Ir para o conteúdo

Jorge Barriuso

@drjorgebarriuso.bsky.social did:plc:la5yqfbrpcahwwqd3f75k4og

Consultant (clinician-scientist) in medical oncology with an interest in Lower GI malignancies including appendix tumours and peritoneal metastasis. #H12O #imas12 #rarecancers #translationalresearch #drugdevelopment

No Bluesky desde

Seguidores
51
Seguindo
17
Posts
28
Dias nos rankings
0

Resumo

Jorge Barriuso (@drjorgebarriuso.bsky.social) é um usuário do Bluesky desde 25 novembro 2024. Tem 51 seguidores, segue 17 contas e publicou 28 posts.

Aparições nos rankings

Os melhores dias em que posts desta conta entraram na lista diária do Debya.

Esta conta ainda não apareceu em um ranking diário.

Posts curtidos recentemente

Curtidas públicas da rede Bluesky.

  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Changing the cytotoxic payload may help to overcome resistance to antibody–drug conjugates (#ADCs). Rachel Abelman discusses studies investigating this strategy to improve patient responses in #BreastCancer #InsightsbyESMO ➡️ https://ow.ly/96mf5100brC

    Ver post
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Early-phase #ClinicalTrial results with the novel bispecific antibodies, pumitamig and opamtistomig, reflect a growing body of research in #NeuroendocrineCarcinoma #InsightsbyESMO ➡️ https://ow.ly/oxLC5100p7J #NENs #NECs #RareCancers

    Ver post
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    👉 #ESMONovelTherapies27: Novel therapies are changing oncology. Are you ready to optimise them in practice? -Understand the science -Select the right patients -Navigate treatment sequencing -Manage toxicities 🔗 https://ow.ly/vIkz50ZZAHh

    Ver post
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Preliminary data support encorafenib and cetuximab #rechallenge in metastatic colorectal cancer (#mCRC), although questions remain around patient selection and treatment specifications, as discussed by Rona Yaeger 🔗 https://ow.ly/6bmH5100p2M #InsightsbyESMO

    Ver post
  • ESMO - European Society for Medical Oncology@myesmo.bsky.social

    #ESMO26: Phase III PERSEE #ClinicalTrial reports a 44% reduction in the risk of progression or death with the addition of #chemotherapy to pembrolizumab versus pembrolizumab alone in first-line advanced #NSCLC with #PD-L1 ≥50% ➡️ https://ow.ly/eWmC5100p3O #InsightsbyESMO Alfredo Addeo

    Ver post

Entre para ver mais

Contas que bloqueia

No Bluesky, bloqueios são registros públicos.

Esta conta não bloqueia ninguém.